4-[4-(2-Chloroethyl)phenyl]-1,3-thiazol-2-amine | 117359-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[4-(2-Chloroethyl)phenyl]-1,3-thiazol-2-amine
• 英文别名: 2-amino-4-(4-(2-chloroethyl)-phenyl)thiazole
• CAS: 117359-54-3
• 化学式: C₁₁H₁₁ClN₂S
• 分子量: 238.741
• InChiKey: FGJPOWBNULYFQN-UHFFFAOYSA-N

物化性质

• 沸点：
  429.2±33.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[4-(2-Chloroethyl)phenyl]-1,3-thiazol-2-amine 在 三乙胺 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.25h， 生成 4-(4-((4-(2-aminothiazol-4-yl)phen)ethyl)piperazin-1-yl)butan-1-ol
  参考文献：
  名称：

  Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues

  摘要：

  A series of twenty six new 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine analogues were synthesized by seven steps and evaluated for their anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain. Among the tested compounds, 7j, 7p, and 7r exhibited moderate activity (MIC = 6.25 μg/mL) and compounds 7a, 7f, 7g, 7n and 7v exhibited good activity (MIC = 3.125 μg/mL), while 7h displayed excellent activity (MIC = 1.56 μg/mL) by inhibiting 99% growth of M. tuberculosis H37Rv strain. In addition, all the active compounds were subjected to cytotoxic studies against mouse macrophage (RAW264.7) cell lines and the selectivity index values for most of the compounds is >10 indicating suitability of compounds in an endeavour to attain lead molecule for further drug development.

  DOI：

  10.1016/j.ejmech.2014.07.067
• 作为产物：
  描述：

  邻氯乙苯 在 aluminum (III) chloride 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 4.0h， 生成 4-[4-(2-Chloroethyl)phenyl]-1,3-thiazol-2-amine
  参考文献：
  名称：

  Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues

  摘要：

  A series of twenty six new 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine analogues were synthesized by seven steps and evaluated for their anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain. Among the tested compounds, 7j, 7p, and 7r exhibited moderate activity (MIC = 6.25 μg/mL) and compounds 7a, 7f, 7g, 7n and 7v exhibited good activity (MIC = 3.125 μg/mL), while 7h displayed excellent activity (MIC = 1.56 μg/mL) by inhibiting 99% growth of M. tuberculosis H37Rv strain. In addition, all the active compounds were subjected to cytotoxic studies against mouse macrophage (RAW264.7) cell lines and the selectivity index values for most of the compounds is >10 indicating suitability of compounds in an endeavour to attain lead molecule for further drug development.

  DOI：

  10.1016/j.ejmech.2014.07.067

文献信息

• Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice
  作者：P Srinivas、A.R Subramanian、P Brust、S.A.V Raghavan、J.B Rangisetty、C.N.V.H.B Gupta、N Sridhar、A Veeranjaneyulu、P Parimoo

  DOI：10.1016/s0014-827x(99)00058-0

  日期：1999.8

  antipsychotic agents, one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system. The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine (7) is described. Compound 7e, 5-2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2

  在开发新的非典型抗精神病药的研究中，一种策略是可以通过操纵血清素能系统来调节多巴胺能系统。描述了基于1-（1,2-二氢-2-ac烯基）哌嗪（7）结构的一系列潜在的非典型抗精神病药的合成和初步药理学评估。来自该系列的化合物7e，5- 2- [4-（1,2-二氢-2-ac烯基）哌嗪基]乙基} -2,3-二氢dro-1H-吲哚-2-酮在5-HT1A和5-HT2A受体对D2受体的亲和力适中。7e表现出由氟哌啶醇引起的僵直症的高度逆转，表明其非典型的抗精神病药性。
• Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
  申请人：PFIZER INC.

  公开号：EP0279598A2

  公开（公告）日：1988-08-24

  An arylpiperazinyl-alkylenephenyl-p-heterocyclic compound, useful in the treatment of psychotic disorders, of the formula- or a pharmaceutically-acceptable acid-addition salt thereof, wherein:-     Ar is phenyl, 3-trifluoromethylphenyl, 3-cyanopyridyl, naphthyl, or a five- or six-membered aromatic heterocyclic ring, said ring being attached to the N atom of the adjacent piperazinyl group by a carbon atom and having one nitrogen, oxygen or sulfur, or two nitrogens one of which may be replaced by oxygen or sulfur, or said heterocyclic ring is condensed with benzo, said naphthyl, heterocyclic and benzoheterocyclic rings being optionally substituted by one fluoro, chloro or trifluoromethyl substituent, said substitution in the case of said naphthyl and benzoheterocyclic rings being in the ring not attached to the piperazinyl group;     n is 2, 3 or 4; and "Het" is a group of the formula:- in which R is H or C₁-C₃ alkyl, and Y is -H, -OH, -SH, -NH₂, C₁-C₃ alkyl or C₁-C₃ alkylamino.

  一种可用于治疗精神病的芳基哌嗪基-烯丙基-对杂环化合物，其式为 或其药学上可接受的酸加成盐、 其中 Ar 是苯基、3-三氟甲基苯基、3-氰基吡啶基、萘基或五元或六元芳香杂环，所述环通过一个碳原子连接到相邻哌嗪基团的 N 原子上，并具有一个氮、氧或硫，或两个硝基，其中一个可被氧或硫取代、或所述杂环与苯并缩合，所述萘环、杂环和苯并杂环可任选被一个氟、氯或三氟甲基取代基取代，所述萘环和苯并杂环的取代基位于未与哌嗪基相连的环上； n 是 2、3 或 4； Het "是式中的一个基团 其中 R 是 H 或 C₁-C₃ 烷基、 Y 是-H、-OH、-SH、-NH₂、C₁-C₃ 烷基或 C₁-C₃ 烷基氨基。
• Arylpiperidine derivatives
  申请人：PFIZER INC.

  公开号：EP0372776A2

  公开（公告）日：1990-06-13

  A series of novel N-alkyl or oxyalkyl arylpiperidine derivatives have been prepared, including their pharmaceutically acceptable acid addition salts, wherein the N-alkyl or oxyalkyl side chain is further substituted by certain aryl or heterocyclic ring groups. These particular compounds are useful in therapy as neuroleptic agents for the control of various psychotic disorders. Typical and preferred member compounds include 4-4-4-(2-­methoxyphenyl)-1-piperidinyl]ethyl}phenyl}}thiazole-2-­amine, 4-4-4-[4-(2-methoxyphenyl)-1-piperidinyl]-n-­butyl}phenyl}}thiazole-2-amine, 3-4-[4-(2-methoxy­phenyl)-1-piperidinyl]-n-butyl}-1,8,8-trimethyl-3-­azabicyclo[3.2.1]heptane-2,4-dione, 5-2-[4-(2-methoxy­phenyl)-1-piperidinyl]ethyl}oxindole and 3-2-[4-(1-­naphthyl)-1-piperidinyl]ethyl}2-methyl-4H-pyrido­[1,2-a]pyrimidine-4-one, respectively. Methods for preparing all these compounds from known starting materials are provided.

  现已制备出一系列新型 N-烷基或氧烷基芳基哌啶衍生物，包括其药学上可接受的酸加成盐，其中 N-烷基或氧烷基侧链进一步被某些芳基或杂环基团取代。这些特殊化合物可作为神经安定剂用于治疗，控制各种精神障碍。典型和优选的成员化合物包括 4-4-4-(2-甲氧基苯基)-1-哌啶基]乙基}苯基}噻唑-2-胺、4-4-4-[4-(2-甲氧基苯基)-1-哌啶基]-正丁基}苯基}噻唑-2-胺、3-4-[4-(2-甲氧基苯基)-1-哌啶基]-正丁基}-1,8,8-三甲基-3-氮杂双环[3.2.1]庚烷-2,4-二酮、5-2-[4-（2-甲氧基苯基）-1-哌啶基]乙基}氧化吲哚和 3-2-[4-（1-萘基）-1-哌啶基]乙基}2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮。本文提供了用已知起始原料制备所有这些化合物的方法。
• Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents
  作者：K.V.G. Chandra Sekhar、V.S. Rao、Devambatla Ravi Kumar Vyas、M. Murali Krishna Kumar

  DOI：10.1016/j.bmcl.2008.10.035

  日期：2008.12

  A series of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides were synthesized in an effort to prepare novel atypical antipsychotic agents. The compounds were synthesized by either microwave irradiation technique or by conventional synthesis and were characterized by spectral data (IR, H-1 NMR, and MS) and the purity was ascertained by microanalysis. All the synthesized compounds were screened for their in vivo pharmacological activity in Swiss albino mice. D-2 antagonism studies were performed using climbing mouse assay model and 5-HT2A antagonism studies were performed using quipazine induced head twitches in mice. It was observed that none of the new chemical entities exhibited catalepsy. AG 3 was found to be the most active compound. (C) 2008 Elsevier Ltd. All rights reserved.
• Parallel-compound synthesis: Methodology for accelerating drug discovery
  作者：Christopher N. Selway、Nicholas K. Terrett

  DOI：10.1016/0968-0896(96)00058-2

  日期：1996.5

  Parallel compound synthesis enables large numbers of individual compounds to be prepared simultaneously using semiautomated techniques. This fast and efficient methodology has an important role to play in accelerating lead optimisation and hence the whole drug discovery process. The potential of this strategy to rapidly optimise chemical leads and provide structure-activity relationship (SAR) information was demonstrated in two therapeutic areas, antiviral agents (herpes simplex virus), and neurokinin-2 receptor antagonists. Copyright (C) 1996 Elsevier Science Ltd.